NBIX releases Phase 2 data. NBY and SPPI initiate Phase 2 trials

May 18, 2012 No Comments by

Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced the initiation of a Phase 2 trial of ZEVALIN for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL).

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced efficacy and safety results from its Phase 2 trial of urocortin 2 in 53 patients with acute decompensated heart failure. Mean arterial pressures were significantly reduced (p<0.001) from 92 +/- 3 mmHg at baseline to 80+/-3 mmHg at end of the urocortin 2 infusion (n=27) in contrast to placebo (n=26) where the mean arterial pressure was 92 +/- 3 mmHg at baseline and 89 +/- 4 mmHg at the end of the placebo infusion. Heart rates were slightly higher during urocortin 2 infusion than placebo although these remained in normal range and comparable in both groups post infusion. In the subset of subjects undergoing right heart catheterization (n=20, 10 per arm), cardiac output increased markedly by over 50% in those randomized to urocortin 2 compared to unchanging values in the placebo group (p=0.003). The company will require a partner for further development.

NovaBay Pharmaceuticals, Inc. (NYSE AMEX: NBY) announced that it has commenced enrolment in a Phase 2b trial named BAYnovationTM, evaluating NVC-422, for the treatment of adenoviral conjunctivitis. Top-line data are expected in 1H 2013. It also noted that a Phase 2b trial of NVC-422 for the treatment of highly contagious skin infection, impetigo, is planned for 2012. Also, top-line results from Part B of its Phase 2b trial of NVC-422 for patients with urinary catheter blockage and encrustation (UCBE), are expected later in 2012.

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “NBIX releases Phase 2 data. NBY and SPPI initiate Phase 2 trials”

Leave a Reply